Last reviewed · How we verify

Scripps Poway Eyecare and Optometry — Portfolio Competitive Intelligence Brief

Scripps Poway Eyecare and Optometry pipeline: 4 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Systane Complete Multi-Dose PF Systane Complete Multi-Dose PF marketed
Refresh Optive MEGA-3 Refresh Optive MEGA-3 marketed Artificial tear lubricant / Ocular surface protectant Ophthalmology
Walgreen's Lubricant Balance Walgreen's Lubricant Balance marketed Artificial tear / Lubricant Ophthalmology
Systane PRO Systane PRO marketed Ophthalmic lubricant / artificial tear Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 1 shared drug class
  2. EMS · 1 shared drug class
  3. Massachusetts Eye and Ear Infirmary · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Scripps Poway Eyecare and Optometry:

Cite this brief

Drug Landscape (2026). Scripps Poway Eyecare and Optometry — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/scripps-poway-eyecare-and-optometry. Accessed 2026-05-16.

Related